


KOPRAN LIMITED
UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30th SEPTEMBER, 2013

Part I	(₹. in lakhs)					
Particulars	Quarter ended			Six Months ended		Year ended
	30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Net Sales / Income from Operations	7854	5810	6290	13664	11,258	24,330
Other Operating Income	237	160	183	397	315	692
Total Income from operations	8091	5970	6473	14061	11573	25022
Expenditure						
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	(371)	(256)	45	(627)	(399)	(408)
Cost of Materials Consumed	4968	3869	3960	8837	7,442	15,823
Purchase of Stock- in - trade	82	60	-	142	-	-
Employee Benefits Expenses	615	524	452	1139	869	2,048
Depreciation	308	303	302	611	598	1,208
Other Expenses	1350	990	1065	2340	1,951	4,129
Total Expenses	6952	5490	5824	12442	10,461	22,800
Profit (Loss) from operations before other income, Interest and exceptional items	1,139	480	649	1,619	1,112	2,222
Other Income	2	2	45	4	91	205
Foregin Exchange Gain/ (Loss)	(263)	104	(90)	(159)	(76)	(33)
Profit (Loss) before Interest and exceptional items	878	586	604	1,464	1,127	2,394
Finance Cost	375	307	281	682	553	1,188
Profit (Loss) before exceptional items	503	279	323	782	574	1,206
Exceptional Items	-	-	-	-	-	-
Profit (Loss) before tax	503	279	323	782	574	1,206
Less :Tax expenses	-	-	-	-	-	-
Net Profit for the period	503	279	323	782	574	1,206
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	8,048
Earning Per Share (EPS) before and after Exceptional Item						
a) Basic	1.29	0.71	0.83	2.00	1.47	3.09
b) Diluted	1.29	0.71	0.83	2.00	1.47	3.09
Part II						
(A) PARTICULARS OF SHAREHOLDING						
Public shareholding						
Number of shares	23956538	23956538	25809523	23956538	25809523	25510073
Percentage of shareholding	61.35%	61.35%	66.09%	61.35%	66.09%	65.33%
Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
Number of shares	3352500	1852500	552500	3352500	552500	1852500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	22.21%	12.27%	4.17%	22.21%	4.17%	13.68%
Percentage of shares (as a % of the total share capital of the company)	8.59%	4.74%	1.42%	8.59%	1.42%	4.74%
b) Non - encumbered						
Number of shares	11740438	13240438	12687453	11740438	12687453	11686903
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	77.79%	87.73%	95.83%	77.79%	95.83%	86.32%
Percentage of shares (as a % of the total share capital of the company)	30.06%	33.91%	32.49%	30.06%	32.49%	29.93%

(B) INVESTOR COMPLAINTS		3 Months ended 30/09/2013					
Pending at the beginning of the quarter		-					
Received during the quarter		-					
Disposed off during the quarter		-					
Remaining unresolved at the end of the quarter		-					
Reporting of Segment wise Revenue,Result and Capital Employed							
Particulars		Quarter ended			Six Months ended		Year ended
		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/03/2013
1. Segment Revenue		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Pharamaceutical		8,207	6,110	6,693	14,317	11,958	25,734
(b) Consumer Care Division		75	42	-	117	-	-
Total		8,282	6,152	6,693	14,434	11,958	25,734
Less : Inter-Segment Revenue		-	-	-	-	-	-
Less : Excise Duty		191	182	220	373	385	712
Net Sales/ Income from Operation		8,091	5,970	6,473	14,061	11,573	25,022
2. Segment Results							
(a) Pharamaceutical		951	615	603	1,566	1,127	2,394
(b) Consumer Care Division		(73)	(29)	-	(102)	-	-
Total		878	586	603	1,464	1,127	2,394
Less: Finance Cost		375	307	281	682	553	1,188
Total Profit Before Tax		503	279	322	782	574	1,206
3. Capital Employed							
(a) Pharamaceutical		19,827	18,167	17,301	19,827	17,301	17,631
(b) Consumer Care Division		196	35	-	196	-	-
(c) Others (Unallocated)		5,424	5,481	5,390	5,424	5,390	5,419
Total		25,447	23,683	22,691	25,447	22,691	23,050
Notes:-							
(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 13th November,2013. Limited review has been carried out by statutory auditor of the company.							
(2) Auditors observation:							
a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 30-09-2013 amounting to Rs. 5237.23 Lacs,(as at 30-09-2012 Rs 5202.96 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.							
(3) Figures for the previous accounting period have been regrouped wherever necessary.							



Kopran

(4) Statement of Assets and Liability			
(₹. in lakhs)			
Particulars	As at	As at	
	30-09-2013	31-03-2013	
	Unaudited	Audited	
I. EQUITY AND LIABILITIES			
1. Shareholders Funds			
(a) Share Capital	4763	4763	
(b) Reserves and Surplus	8830	8048	
Total	13593	12811	
2. Non-current liabilities			
(a) Long-term borrowings	6920	6948	
(b) Long-term provisions	368	357	
Total	7288	7305	
3. Current liabilities			
(a) Short-term borrowings	3728	2437	
(b) Trade payables	3504	4684	
(c) Other current liabilities	2333	2056	
(d) Short-term provisions	12	12	
Total	9577	9189	
TOTAL	30458	29305	
II. ASSETS			
1. Non-current assets			
(a) Fixed Assets			
(i) Tangible assets	10347	10618	
(ii) Capital work-in-progress	84	93	
(b) Non-current investment	687	687	
(c) Long-term loans and advances	5867	5597	
Total	16985	16995	
2. Current assets			
(a) Inventories	4767	3674	
(b) Trade receivables	3973	4961	
(c) Cash and Bank balances	468	363	
(d) Short-term loans and advances	4265	3312	
Total	13473	12310	
TOTAL	30458	29305	
<div>KOPRAN LIMITED</div> <div></div> <div>Surendra Somani Executive Vice Chairman</div> <div>Place : Mumbai Date: 13-11-2013</div>			

